CRMD vs RLMD: stock comparison and AI forecast
Cormedix Inc. (CRMD) and Relmada Therapeutics, Inc. (RLMD) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CRMD Cormedix Inc.
- Price
- $5.23 -34.0% · 6M
- Market Cap
- $408M
- P/E Ratio
- 2.6x
- Size
- small-cap
- AI Forecast
RLMD Relmada Therapeutics, Inc.
- Market Cap
- $402M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- CRMD and RLMD have similar market capitalizations ($408M and $402M).
- CRMD carries 0.96 times debt per unit of equity, against 0.06 times for RLMD.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CRMD | RLMD |
|---|---|---|
| Market Cap | $408M | $402M |
| P/E Ratio | 2.55x | – |
| P/B Ratio | 0.88x | 1.95x |
| EPS | $2.05 | $-1.26 |
| Book Value/Share | $5.91 | $1.94 |
| Revenue/Share | $5.80 | – |
| FCF/Share | $3.21 | – |
Profitability & Margins
| Metric | CRMD | RLMD |
|---|---|---|
| ROE | 40.6% | – |
| ROA | 20.7% | – |
| ROIC | 30.3% | -30.8% |
| Gross Margin | 90.0% | – |
| Operating Margin | 48.0% | – |
| Net Margin | 41.4% | – |
| EBT Margin | 45.0% | – |
| Tax Rate | 8.0% | – |
Financial Health
| Metric | CRMD | RLMD |
|---|---|---|
| Current Ratio | 2.56x | 29.52x |
| Quick Ratio | 2.36x | – |
| D/E Ratio | 0.96x | 0.06x |
| Financial Leverage | 1.96x | 1.06x |
| Interest Coverage | 15.2x | -21.3x |
| Working Capital | $293M | $212M |
Cash Flow
| Metric | CRMD | RLMD |
|---|---|---|
| Operating Cash Flow | $254M | -$46M |
| Free Cash Flow | $250M | – |
| Capital Spending | -$4M | – |
| OCF Growth YoY | 733.6% | – |
| FCF Growth YoY | 723.5% | – |
| FCF/Sales | 55.4% | – |
| CapEx/Sales | 0.8% | – |
Operational Efficiency
| Metric | CRMD | RLMD |
|---|---|---|
| Asset Turnover | 0.50x | – |
| Receivables Turnover | 2.8x | – |
| Inventory Turnover | 1.2x | – |
| Fixed Assets Turnover | 57.6x | – |
| Days Sales Outstanding | 130 days | – |
| Days Inventory | 312 days | – |
| Payables Period | 83 days | – |
| Cash Conversion Cycle | 359 days | – |
Income Statement
| Metric | CRMD | RLMD |
|---|---|---|
| Total Revenue | $452M | – |
| Operating Income | $217M | -$65M |
| Net Income | $187M | – |
| R&D Expense | $28M | $29M |
| SG&A Expense | $171M | – |
| Cost of Goods Sold | $45M | – |
Dividend & Shareholder Information
| Metric | CRMD | RLMD |
|---|---|---|
| Shares Outstanding | 78M | 107M |
| Net Income Growth | 265.9% | – |
| EPS Growth | 791.3% | – |
CRMD vs RLMD: stock comparison and AI forecast
Which is bigger, CRMD or RLMD?
CRMD and RLMD have similar market capitalizations ($408M and $402M).
Which one does Intratio's AI model rank higher, CRMD or RLMD?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.